These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36044111)

  • 1. Direct and indirect savings from parallel imports in Sweden.
    Granlund D
    Health Econ Rev; 2022 Aug; 12(1):46. PubMed ID: 36044111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Kanavos P; Taylor D
    Curr Med Res Opin; 2007 Oct; 23(10):2467-76. PubMed ID: 17764613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What is the real price of SOP and OTC drugs? Pilot study on paracetamol].
    Milozzi F; Di Filippo A; Cangini A; Trotta F
    Epidemiol Prev; 2023; 47(1-2):57-66. PubMed ID: 36727257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discounting of medicines in Australian community pharmacies.
    Thai LP; Vitry AI; Moss JR
    Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel imports under a manufacturer rebate and a price freeze: Evidence from Germany.
    Birg L
    Health Econ; 2023 Feb; 32(2):302-323. PubMed ID: 36336829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics.
    Duso T; Herr A; Suppliet M
    Health Econ; 2014 Sep; 23(9):1036-57. PubMed ID: 25139795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom].
    Costa-Font J; Kanavos P
    Gac Sanit; 2007; 21(1):53-9. PubMed ID: 17306187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illicit drug prices and quantity discounts: A comparison between a cryptomarket, social media, and police data.
    Moeller K; Munksgaard R; Demant J
    Int J Drug Policy; 2021 May; 91():102969. PubMed ID: 33041184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
    Sarpatwari A; Tessema FA; Zakarian M; Najafzadeh MN; Kesselheim AS
    Health Aff (Millwood); 2021 May; 40(5):772-778. PubMed ID: 33939506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel imports of pharmaceuticals in the European Union.
    Darbà J; Rovira J
    Pharmacoeconomics; 1998; 14 Suppl 1():129-36. PubMed ID: 10186474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.